Johnson & Johnson (JNJ) Assets Average (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Assets Average came in at $201.0 billion in Q2 2026, up 3.85% year-over-year from $193.5 billion in Q2 2025, and little changed quarter-over-quarter from $200.1 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Assets Average (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Assets Average across 18 years of filings, most recently posting $201.0 billion for Q2 2026.
- In Q2 2026, Assets Average rose 3.85% year-over-year to $201.0 billion; the TTM figure through Jun 2026 stood at $201.0 billion (up 3.85% YoY), while the FY2025 annual figure was $189.7 billion, up 9.1% from the prior year.
- Assets Average came in at $201.0 billion for Q2 2026 at Johnson & Johnson, roughly flat from $200.1 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $201.0 billion in Q2 2026 to a low of $166.8 billion in Q4 2023.
- Average Assets Average over 5 years is $184.4 billion, with a median of $180.6 billion recorded in 2022.
- Year-over-year, Assets Average fell 11.43% in 2024 and advanced 10.09% in 2025.
- Over 5 years, Assets Average stood at $176.4 billion in 2022, then fell by 5.45% to $166.8 billion in 2023, then grew by 7.43% to $179.2 billion in 2024, then rose by 9.39% to $196.0 billion in 2025, then rose by 2.53% to $201.0 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $201.0 billion in Q2 2026, $200.1 billion in Q1 2026, and $196.0 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.20 Bn | 622.44 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 448.14 Bn | 441.57 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 358.13 Bn | 350.98 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.12 Bn | 11.24 Bn | 120.28 Bn |
| 5 | Pfizer | 156.55 Bn | 144.85 Bn | 10.94 Bn | 204.57 Bn |
| 6 | Sanofi | 52.17 Bn | 44.78 Bn | 10.79 Bn | 149.95 Bn |
| 7 | Revolution Medicines | 42.92 Bn | 42.92 Bn | - | 3.29 Bn |
| 8 | Incyte | 24.72 Bn | 20.19 Bn | 1.57 Bn | 7.61 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn | 6.97 Bn |
| 10 | Neurocrine Biosciences | 15.83 Bn | 15.44 Bn | 935.80 Mn | 5.13 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 200.98 Bn |
| Mar 29, 2026 | 200.05 Bn |
| Dec 28, 2025 | 196.01 Bn |
| Sep 28, 2025 | 193.10 Bn |
| Jun 29, 2025 | 193.53 Bn |
| Mar 30, 2025 | 186.89 Bn |
| Dec 29, 2024 | 179.20 Bn |
| Sep 29, 2024 | 179.69 Bn |
| Jun 30, 2024 | 176.53 Bn |
| Mar 31, 2024 | 169.76 Bn |
| Dec 31, 2023 | 166.81 Bn |
| Oct 1, 2023 | 178.87 Bn |
| Jul 2, 2023 | 193.83 Bn |
| Apr 2, 2023 | 191.67 Bn |
| Jan 1, 2023 | 181.25 Bn |
| Oct 2, 2022 | 176.42 Bn |
| Jul 3, 2022 | 178.04 Bn |
| Apr 3, 2022 | 180.19 Bn |
| Jan 2, 2022 | 180.62 Bn |
| Oct 3, 2021 | 177.83 Bn |